1. Scrip

Three Deaths In Trial Mean Clinical Hold For Juno’s Lead CAR-T Therapy

 
• By Mandy Jackson

Juno Therapeutics Inc. planned to win US FDA approval in 2017 for its chimeric antigen receptor T cell (CAR-T) cell therapy JCAR015, but the company has reached another significant milestone that may delay that goal: its Phase II ROCKET clinical trial in the treatment of adults with relapsed or refractory B cell acute lymphoblastic lymphoma (ALL) has been put on clinical hold due to three deaths.

microscope

Juno Therapeutics Inc. planned to win US FDA approval in 2017 for its chimeric antigen receptor T cell (CAR-T) cell therapy JCAR015, but the company has reached another significant milestone that may delay that goal: its Phase II ROCKET clinical trial in the treatment of adults with relapsed or refractory B cell acute lymphoblastic lymphoma (ALL) has been put on clinical hold due to three deaths.

Juno recently instituted a new pre-conditioning regimen in ROCKET that added fludarabine to cyclophosphamide chemotherapy, which was administered before the company's engineered T cells were injected back into recently enrolled patients

More from Business

More from Scrip

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Executives On The Move: Five CEOs, Three CFOs And Two CMOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Immunovant, Zymeworks and Cassava Sciences, among others, plus Zealand Pharma acquires chief scientific officer from Eli Lilly.